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Abstract
Purpose: To assess the prognostic value of FDG PET/CT compared to the tumor markers S100B and melanoma inhibitory
activity (MIA) in patients with high risk melanoma.
Methods: Retrospective study in 125 consecutive patients with high risk melanoma that underwent FDG PET/CT for re-
staging. Diagnostic accuracy and prognostic value was determined for FDG PET/CT as well as for S100B and MIA. As
standard of reference, cytological, histological, PET/CT or MRI follow-up findings as well as clinical follow-up were used.
Results: Of 125 patients, FDG PET/CT was positive in 62 patients. 37 (29.6%) patients had elevated S100B (.100 pg/ml) and
24 (20.2%) had elevated MIA (.10 pg/ml) values. Overall specificities for FDG PET/CT, S100B and MIA were 96.8% (95% CI,
89.1% to 99.1%), 85.7% (75.0% to 92.3%), and 95.2% (86.9% to 98.4%), corresponding sensitivities were 96.8% (89.0% to
99.1%), 45.2% (33.4% to 55.5%), and 36.1% (25.2% to 48.6%), respectively. The negative predictive values (NPV) for PET/CT,
S100B, and MIA were 96.8% (89.1% to 99.1%), 61.4% (50.9% to 70.9%), and 60.6% (50.8% to 69.7%). The positive predictive
values (PPV) were 96.7% (89.0% to 99.1%), 75.7% (59.9% to 86.6%), and 88.0% (70.0% to 95.8%). Patients with elevated
S100B- or MIA values or PET/CT positive findings showed a significantly (p,0.001 each, univariate Cox regression models)
higher risk of melanoma associated death which was increased 4.2-, 6.5- or 17.2-fold, respectively.
Conclusion: PET/CT has a higher prognostic power in the assessment of cancer-associated mortality in melanoma patients
compared with S100 and MIA.
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Introduction
Accurate staging and follow-up in melanoma patients is
essential for appropriate treatment planning and may improve
survival [1,2,3]. Several parameters with potentially prognostic
value have been identified in melanoma. These include Breslow
thickness, ulceration histological subtype and tumor status of
regional lymph nodes [4]. High risk melanoma patients have a
recurrence and mortality risk higher than 35% to 50% within five
years [5,6].
Serum S100B is a valuable prognostic marker for assessment of
melanoma mortality [7,8]. More than 80% of patients with
metastatic melanoma have elevated S100B levels. Rising levels of
S100B are a useful predictor of a relapse of disease and were found
to give readings 5–23 weeks before other clinical or conventional
radiological methods. Melanoma inhibitory activity (MIA) is a
marker for progression from localized to metastatic disease in
advanced melanomas. MIA possesses a higher specificity in the
detection of metastatic disease compared to S100B and is nega-
tively correlated with survival [7,8]. The serum lactate dehydro-
genase (LDH) level is the currently most important serum marker
of poor prognosis in melanoma patients and has been recently
included into the AJCC staging system [2].
[
18F]-fluoro-deoxy-glucose positronemissiontomography(FDG-
PET) is successfully used for primary staging of patients with
malignant melanoma [9,10]. FDG-PET/CT has a high accuracy
for staging in high risk melanoma patients and is superior to
conventional imaging methods [11,12,13]. Sensitivity and speci-
ficity of PET/CT in staging of malignant melanoma are
approximately 98%. However, its role in follow-up is controversial
and it is important to identify clinical situations where PET/CT
has a therapeutic impact. In patients with high risk melanoma
PET/CT may help to detect recurrence or metastatic disease and
to initiate a specific therapy. The prognostic value of PET/CT in
high risk melanoma patients compared to the tumor markers
S100B and MIA has not been assessed [14].
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Ethics statement
The retrospective study was approved by the ‘‘Ethical Board’’ of
the ‘‘Technische Universita ¨t Mu ¨nchen’’. Written informed
consent was available from all patients.
Participants
125 consecutive patients with suspected metastases of malignant
melanoma were included between November 2003 and May
2006. Patients who had a Breslow tumor thickness .2.0 mm,
elevated S100B or MIA level, a sentinel lymph node positive for
tumor or a known/resected metastasis in the history were selected.
All patients were AJCC stage IIB or higher or had suspicious
findings in ultrasound. The age of the patients was in mean
58.8614.1 years, 58 were female (46.4%) and 67 (53.6%) patients
were male (Table 1).
PET/CT-Imaging
Patients were scanned with a Biograph 16 PET/CT (Siemens
Medical Solutions, Erlangen, Germany) after injection of [
18F]-
FDG (5 MBq/kg body weight). The scans were performed
60 minutes after injection of the tracer. Patients fasted six hours
before the PET examination and the blood glucose level was
,150 mg/dl in all patients. Whole body images were acquired
from all patients, i.e. 15 bed positions a ´ 2 minutes acquisition time.
59 patients received a contrast enhanced CT including the
application of 300 ml Imeron as contrast media. Oral contrast
media was administered 30 minutes before injection of FDG.
Image analysis was performed using TrueD software (Siemens
Medical Systems, Malvern, PA). All studies were analyzed
independently by two experienced nuclear medicine specialists
who were blinded to patient outcome. Prior clinical reports of
these studies were not taken into account. In visual assessment
focal, non physiological FDG-uptake was defined as consistent
with tumour tissue. For quantitative analysis of FDG-uptake
standardized uptake values (SUV) were measured using 3
dimensional regions of interest in TrueD software.
Standard of Reference
Lymph node or distant metastases found by PET/CT were
confirmed by histology, by follow up PET/CT, MRI, by clinical
follow for up to 18–48 month or tumor associated death. A false
positive PET/CT diagnosis was determined if histology of the
lesion or clinical follow-up ruled out metastases (disappearance of
lesions without therapy) or if MRI indicated a different etiology.
False negative metastases were confirmed by clinical follow-up,
death of the patient or MRI.
Measurement of the tumor markers S100 and MIA
S100B-levels were determined with a commercial sandwich
electrochemiluminescence immunoassay (ECLIA) of the Elecsys
2010-system from Roche (Mannheim, Germany). With an
interassay coefficient variation of 2.0 to 2.8% in human serum
(manufacturer’s information) the measuring range reaches from 5
to 3900 pg/ml. As recommended by the manufacturer, samples
with S100B-concentrations .3900 pg/ml were diluted 1 : 5 with
the low calibrator of CalSet S100 (Roche). For all measurements, a
voluntary quality control according to the ‘‘Guidelines of the
Federal Medical Association for quality assurance in laboratory
medicine investigations’’ (RiliBA ¨K) was performed. The cut-off
value for S100 was 100 pg/ml. The serum concentration of MIA
was determined by ELISA using a commercial assay kit (Roche)
according to the manufacturer’s instructions. Briefly, two mono-
clonal antibodies directed against the NH2-terminal- (clone 2F7)
conjugated with horseradish peroxidase or the COO- terminal-
region (clone 1A12) conjugated with biotin were used. Ten
microliters of serum or standard (recombinant MIA purified from
Chinese Hamster Ovary cells, provided by the manufacturer) were
incubated with 200 ml reagent containing both antibodies in
streptavidin coated 96-well plates for 45 minutes with shaking.
After washing three times with washing buffer (Roche) 200 mlo f
2.2-azino-de(3-ethylbenz-thiazoline sulphonate (Roche) was incu-
bated in the wells for 30 minutes and measured colorimetrically at
405 nm. Using the indicated standard concentrations between
0.1 ng/ml and 50 ng/ml. The 97 percentile was set as a cut-off at
10.0 ng/ml. Also LDH was measured by a commercial kit
according to the manufacturer’s instructions (Roche, Germany).
The cut-off value was 244 U/l. The time between PET/CT and
tumor marker measurement was in mean 16.7 days (median
9 days).
Statistical analysis
Statistical analysis of data was performed using SPSS version
16. All tests were performed using an explorative two-tailed
significance level of a=0.05. For determination of sensitivity,
specificity, positive and negative predictive values of S100, MIA,
LDH or PET/CT, the diagnosis made by these modalities was
compared to the standard of reference. 95% confidence intervals
are presented for all relevant measures. To investigate the
diagnostic accuracy of the tumor markers and to determine
thresholds for identification of progressive disease Receiver
Operating Characteristic (ROC) analyses were conducted. The
Youden-Index (=sensitivity + specificity 2 1) was calculated to
obtain optimal cut-off values. To determine the univariate
correlation of S100B, MIA and LDH with survival quantitative
values were dichotomized. Survival probabilities were estimated
by Kaplan-Meier method. To evaluate the association of
diagnostic modalities with survival and to estimate corresponding
hazard ratios Cox regression models were fitted. The overall C
index was determined as a measure of discrimination between
events and non-events. The index represents the proportion of all
usable pairs in which predictions and outcomes are concordant
[15]. Values closer to one indicate better discrimination.
Results
Sensitivity and specificity of FDG PET/CT in the detection
of recurrence/metastases of high risk melanoma
The standard of reference defined 62 patients (49.6%) as having
recurrent or metastatic melanoma (Table 2). In FDG PET/CT, 62
patients were positive for tumor and 63 did not show metastases or
recurrence. Two patients were false positive and two were false
Table 1. Patient characteristics.
Sex Age T-stadium Metastasis
male: 58 (56.4%) mean age: 58.8 years T1: 24 Skin: 7
female: 67 (53.6%) range: 26.4–88. T2: 26 Lymph nodes: 33
T3: 26 visceral: 22
T4: 26 no metastasis: 63
CUP: 23
doi:10.1371/journal.pone.0024632.t001
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detect tumor tissue in high risk melanoma patients was 96.8%
each (95% confidence interval (CI) 89.0% to 99.1% and.89.1% to
99.1%) (Table 2).
Sensitivity and specificity of the tumor markers S100B
and MIA in the detection of recurrence/metastases of
high risk melanoma
Out of 125 patients 98 had normal and 26 had elevated MIA
levels. From one patient MIA was not available. 39 patients were
false negative and 3 were false positive. Moreover, 88 patients had
normal S100B and 37 had elevated S100B levels. 34 patients were
false negative and 9 were false positive. In the group negative for
tumour tissue according to the gold standard S100 was in mean
66.9634.7 pg/ml (median 58 pg/ml, maximum 190, minimum
27 pg/ml). MIA was in mean 6.662.1 ng/ml (median 6.1 ng/ml,
maximum 14.6, minimum 2.1 ng/ml). In the group positive for
tumour tissue S100 was in mean 2036383 ng/ml (median 73 ng/
ml, maximum 2285 ng/ml, minimum 23 ng/ml). The sensitivity
and specificity for S100B were 45.2% (95% CI, 33.4% to 57.5%)
and 85.7% (75.0% to 92.3%) and for MIA 36.1% (25.2% to
48.6%) and 95.2% (86.9% to 98.4%) (Table 3). In a subgroup of
58 patients LDH was also determined. Using a cut-off value of
244 U/l 33 patients had elevated LDH values and 25 had normal
LDH values. The sensitivity to detect metastasis/recurrence was
30.3% (95% CI, 17.4% to 47.3%) and the specificity 96.0%
(80.5% to 99.8%). A ROC-analysis revealed that the area-under-
the-curve for S100, MIA and LDH were 0.685, 0.681 and
0.619.The NPVs of PET/CT, S100, and MIA were 96.8% (95%
CI, 89.1% to 99.1%), 61.4% (50.9% to 70.9%), and 60.6% (50.8%
to 69.7%). The PPVs were 96.8% (89.0% to 99.1%), 75.7%
(59.9% to 86.6%), and 88.0% (70.0% to 95.8%). In a subgroup of
58 patients LDH was measured and a NPV of 51.1% (37.2% to
64.7%) and a PPV of 90.9% (62.2% to 99.5%) was found (Table 3).
A multivariate analysis revealed that a combination of FDG PET/
CT, S100B and MIA did not improve the sensitivity and specificity
to detect metastases in high risk melanoma patients.
Prognostic value of FDG PET/CT, S100B and MIA in high
risk melanoma patients
Kaplan-Meier survival curves are presented in Figure 1. In the
group indicated as tumor-positive by PET 25 patients died (25 of
62 patients). In the group indicated as negative by PET 2 died (2
of 63 patients). By measuring S100B, 88 patients were denoted
negative for recurrence and 37 positive. In the S100B-positive
group 15 patients died (15 of 37 patients). In the S100B-negative
group 12 patients died (12 of 88 patients). By measuring MIA,
99 patients were identified as negative for tumor and 25 patients
were identified as positive. In the MIA-negative group 13 died
from melanoma (13 of 99 patients). In the MIA-positive group 13
died (13 of 25 patients). The difference in melanoma associated
mortality between patients with pathological findings in FDG
PET/CT or elevated tumor markers and patients with normal
tumor markers or non pathologic PET/CT was statistically sig-
nificant (Cox regression, p,0.001). Patients with positive findings
in PET/CT had a 17.2-fold higher mortality risk compared to
patients with normal PET/CT. Patients with elevated MIA-,
S100B- or LDH-levels had a 6.5-fold, 4.2-fold or 6.1-fold higher
mortality risk compared to patients with normal tumor markers
(Table 4). Analyses adjusted for age and gender revealed similar
results (not shown). The median survival in the S100B-, MIA-,
LDH-, or PET/CT-positive groups was 29.7 months (95% CI not
determinable), 16.4 months (95% CI, 1.5 to 31.3), 16.4 months
(6.7 to 26.1) or 43.87 months (19.6 to 68.1) (Table 4), indicating
that in patients with truly positive tumor markers the survival is
shorter, compared with patients who are positive in PET/CT
only. The C index was highest for PET/CT indicating best
discrimination (C-Index PET/CT: 0.93; LDH: 0.87; S100: 0.85;
MIA: 0.88; Table 4). To test whether FDG-uptake in metastases is
correlated to prognosis we determined the mean standardized
uptake value (SUVmean) in all pathological lesions and correlated
the SUV to the survival of patients. We found no statistically
significant correlation of SUVmean and survival in our patient
group taking M-stage and the bulk of disease into account
(p=0.158, HR=0.943). We also analyzed if there is a quantitative
relationship between S100- or MIA-level and survival. For S100
the Hazard ratio was 1.001 (95% CI 0.9997 to 1.0015, p=0.189).
Therefore, we did not find a statistically significant correlation of
the S100 level and survival. For MIA the Hazard ratio was 1.046
(95% CI 1.026 to 1.066, p,0.001). These values indicate a
statistically significant relation between the MIA-level and
survival. In the group indicated as tumour positive, 45 patients
received chemotherapy, 15 exclusively chemotherapy. 45 patients
were treated with surgery, 14 exclusively with surgery; 29 patients
received surgery and chemotherapy.17 patients were treated with
radiation which was combined with chemotherapy in 16 cases and
with surgery in one case. One patient refused any treatment. With
regard to the low number of patients in these subgroups a
correlation of treatment modality and prognosis could not be
performed.
Correlation of the number of PET/CT-positive metastases
and survival
We compared the melanoma associated mortality risk of
patients with different numbers of metastases. Group-1 had no
metastases, group-2 one metastasis, group-3 1–5 metastases and
group-4 had more than 5 metastases. Kaplan-Meier survival
curves were plotted for all four groups. In group-1 (63 patients) two
died. In group-2 (23 patients) 7 died. In group-3 (14 patients) 6
died. In group-4 (25 patients) 12 died. Mortality rates were
correlated with the number of metastases (p,0.001).
Table 2. Patients positive or negative for recurrent/metastata-
sized melanoma in PET/CT, S100, MIA and standard of reference.
S100B MIA PET/CT standard
elevated: 37 elevated: 25 recurrence:
62
recurrence:
64
not elevated: 88 not elevated: 99 no recurrence:
63
no recurrence:
61
doi:10.1371/journal.pone.0024632.t002
Table 3. Melanoma restaging.
PET/CT (95% CI) S100B (95% CI) MIA (95% CI)
specificity 96.8% (89.0–99.1) 85.7% (75.03–92.30) 95.2% (86.91–98.37)
sensitivity 96.8% (89.1–99.1) 45.2% (33.42–57.47) 36.1% (25.17–48.61)
NPV 96.8% (89.1–99.1) 61.4% (50.2–70.9) 60.6% (50.8–69.7)
PPV 96.8% (89.98–99.1) 75.7% (59.9–86.64) 88.0% (70.04–95.8)
doi:10.1371/journal.pone.0024632.t003
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positivity
For the analysis of the temporal relation of FDG PET/CT and
tumor marker positivity we analyzed a sub-group of 42 patients
truly positive for metastastatic disease according to the standard of
reference. The tumor markers became positive after 538 days in
median (range 8–7371) after initial diagnosis and PET/CT
became positive in median after 565 days (range 125–829). In
13/42 patients (31%) metastatic disease was detected by PET but
the tumor markers never became positive. In 12/42 patients (29%)
tumor markers and PET/CT were found to be elevated at the
same time. In 6/42 patients (14%) the tumor markers became
positive later than FDG PET/CT. In 11/42 (26%) of patients the
tumor markers became positive earlier compared to PET/CT.
Therefore in a relevant number of patients with metastatic disease
positive in FDG PET/CT the tumor markers were never elevated.
Discussion
We analyzed the predictive values, sensitivity and specificity of
FDG PET/CT compared with the tumor markers S100B and
MIA in the follow-up of high risk melanoma patients. All three
biomarkers detect metastases of malignant melanoma with clini-
cally valuable sensitivity and specificity. Among these, FDG PET/
CT is by far the most effective modality. Sensitivity and specificity
of PET/CT were 96.8% each. Only two false positive od two false
negative studies were found in our collective of melanoma patients.
Both false negative patients had brain metastases which could not
be detected due to the high physiological glucose metabolism in
Figure 1. Correlation of survival and positive findings in PET/CT (A), S100 (B) MIA (C) and LDH (D). Blue: patients with positive findings.
Green: patients diagnosed negative.
doi:10.1371/journal.pone.0024632.g001
Table 4. Mortality risk (Hazard ratios) in patients positive for
PET/CT, S100B, LDH or MIA.
PET/CT S100B LDH* MIA
Increased mortality 17.2 4.2 6.1 6.5
p-value ,0.001 ,0.001 =0.001 ,0.001
95% CI 4.197–1.948 1.94–9.04 2.1–17.6 2.95–14.3
Median survival 43.87621.37 29.7 16.4 16.4
C-Index 0.933 0.825 0.875 0.881
95% CI 0.654–0.990 0.531–0.951 0.464–0.983 0.581–0.975
*LDH was determined in a sub group of 58 patients.
doi:10.1371/journal.pone.0024632.t004
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brain metastases in high risk melanoma patients. One false positive
patient had a politeal neurinoma. The other false positive patient
had a chromic lymphatic leukemia, mimicking retroperitoneal
lymph node meatstases. The high sensitivity of FDG PET/CT to
detect melanoma metastases is most likely due to the uniquely high
glycolytic activity of melanoma cells leading to intensive FDG-
uptake promoting the detectability of the lesions. The high FDG-
uptake in almost all melanomas is a likely explanation for our
finding that SUVmean is not correlated to survival of patients in
our study collective in a statistically significant manner as it seems
to be a feature of all melanomas and not to be restricted to highly
aggressive subtypes [14]. Therefore, quantification of SUV does
not further contribute to assessment of the mortality risk and the
probability of survival as observed in our study.
FDG PET/CT is more sensitive and more specific in detection
of metastases in high risk melanoma patients compared to the
tumor markers S100B and MIA. S100B-concentration in the
serum is also modulated by factors independent of melanoma
reducing specificity to 85% [16,17]. MIA has a high specificity of
approximately 95%, but its low sensitivity of 36% causes a high
rate of false negative findings [18]. In the present study an ROC
analysis was conducted to evaluate diagnostic properties of S100B
and MIA and to derive thresholds for identification of patients
with metastatic or recurrent disease. Cut-off values found in our
data as well as sensitivities and specificities using dichotomized
markers S100B and MIA are consistent with those previously
reported in literature [16,17].
The lower sensitivity of the tumor markers compared to FDG
PET/CT is puzzling. Presumably, the intense glucose metabolism
in melanoma cells promotes the detection of relatively small tumor
nodules which may be too small to produce enough tumor marker
protein to elevate the serum level significantly. It is surprising that
in FDG PET/CT negative patients, no patient showed elevated
serum level of MIA or S100B or melanoma associated death
during follow up. Therefore the macroscopic disease as evidenced
by PET/CT seems to drive the prognosis and not microscopic
disease.
Although sensitivity and specificity of FDG PET/CT and
S100B have been compared in several studies the differences of
prognostic values of these modalities have not been analyzed
[14,18,19]. It is widely accepted that S100B and MIA are of
prognostic value in stratification of survival probability in high risk
melanoma patients. We found an inverted relationship between
the serum level of S100B and MIA and survival in our collective
[7,8]. Positive findings in FDG PET/CT were associated with a
significantly increased risk of melanoma associated death which
was 17.2-fold higher compared to patients with normal FDG
PET/CT. In comparison, patients with elevated S100B or MIA
experienced a risk of only 4.2-fold or 6.5-fold higher. On the other
hand we found that in patients with truly positive tumor markers
the median survival is shorter compared to patients positive for
recurrence only in PET/CT, indicating that S100B and MIA
detect subgroups of metastasis with poor prognosis (table 4). The
high predictive value of FDG PET/CT to assess the probability of
melanoma associated mortality may be useful to stratify patients
into groups which may benefit from novel therapies. It is
particularly noteworthy that FDG PET/CT discriminates two
groups with different mortality rates. As high risk melanoma is
associated with a mortality risk of up to 50%, it is remarkable that
PET negative patients within this group have a much better
prognosis. As the mortality in PET-positive patients is higher both
groups may require different treatment for example with novel
molecular therapeutics such as mTOR inhibitors. This study
demonstrates the superior prognostic value of FDG PET/CT and
its higher power to discriminate between patient groups with
different mortality risk in high risk melanoma compared to the
tumor markers S100B and MIA. Our data suggest that prospective
trials comparing the prognostic value of PET/CT, S100 and MIA
should be performed. We also propose that for these studies the
recently developed MR/PET should be used potentially improv-
ing the performance of PET as the problem of false negative PET-
studies in patients with brain metastases may be overcome by the
use of combined MR and PET.
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